gsgs
Registered User
http://www.fool.com/investing/high-...ul-flu-production-technology-from-baxter.aspx
trials go well, good profile for side effects.
But Novartis and Glaxo are 1-2 years ahead...
------------------------
...
The most recent clinical trial had a much improved side effect profile, likely due to its change from whole virus to split virus. The split virus process breaks up the viral particles with detergent and allows for lower dosing than whole virus to get the same immune response.
Baxter plans to begin an 11,000-person phase 3 trial later this year. Because immune responses are fairly consistent from person to person, it seems likely that the phase 3 trial results will parallel the recently announced results. Even with a conclusive phase 3 trial, FDA marketing approval is still a ways away. That gives competitors GlaxoSmithKline (NYSE: GSK), Sanofi-Aventis (NYSE: SNY), and Novartis (NYSE: NVS) at least one and possibly two flu seasons before they need to worry about competition from Baxter.
...
Baxter also uses the Vero-cell technology to produce its H5N1 bird flu vaccine that is in phase 3 clinical trials. It has contracts with the U.S. and Australian governments to develop and provide vaccine in case of a pandemic outbreak.
----------------------
shouldn't that be "Austrian" ?
trials go well, good profile for side effects.
But Novartis and Glaxo are 1-2 years ahead...
------------------------
...
The most recent clinical trial had a much improved side effect profile, likely due to its change from whole virus to split virus. The split virus process breaks up the viral particles with detergent and allows for lower dosing than whole virus to get the same immune response.
Baxter plans to begin an 11,000-person phase 3 trial later this year. Because immune responses are fairly consistent from person to person, it seems likely that the phase 3 trial results will parallel the recently announced results. Even with a conclusive phase 3 trial, FDA marketing approval is still a ways away. That gives competitors GlaxoSmithKline (NYSE: GSK), Sanofi-Aventis (NYSE: SNY), and Novartis (NYSE: NVS) at least one and possibly two flu seasons before they need to worry about competition from Baxter.
...
Baxter also uses the Vero-cell technology to produce its H5N1 bird flu vaccine that is in phase 3 clinical trials. It has contracts with the U.S. and Australian governments to develop and provide vaccine in case of a pandemic outbreak.
----------------------
shouldn't that be "Austrian" ?